Abeona Therapeutics (PCJ) Ratios
Abeona Therapeutics Ratios
DE:PCJ's free cash flow for Q2 2026 was $-17.98M. For the 2026 fiscal year, DE:PCJ's free cash flow was decreased by $-479.00K and operating cash flow was $-17.50M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.93 | 6.08 | 4.15 | 6.83 | 3.39 |
| Quick Ratio | 6.74 | 6.08 | 4.15 | 6.83 | 3.39 |
| Cash Ratio | 2.65 | 1.41 | 1.08 | 1.83 | 1.98 |
| Solvency Ratio | 1.24 | -0.94 | -1.04 | -0.94 | -2.16 |
| Operating Cash Flow Ratio | -2.58 | -3.38 | -2.76 | -5.59 | -3.95 |
| Short-Term Operating Cash Flow Coverage | -6.24 | -9.45 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 144.55M | $ 35.95M | $ 6.56M | $ 15.65M | $ 19.07M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.11 | 0.21 | 0.08 | 0.12 | 0.12 |
| Debt-to-Equity Ratio | 0.16 | 0.52 | 0.36 | 0.29 | 0.22 |
| Debt-to-Capital Ratio | 0.14 | 0.34 | 0.27 | 0.22 | 0.18 |
| Long-Term Debt-to-Capital Ratio | 0.05 | 0.23 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.38 | 2.47 | 4.32 | 2.40 | 1.88 |
| Debt Service Coverage Ratio | 4.92 | -5.59 | -120.99 | -46.72 | -21.01 |
| Interest Coverage Ratio | -23.92 | -15.26 | -112.76 | -69.18 | -24.57 |
| Debt to Market Cap | 0.07 | 0.08 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.54 | 0.66 | 0.27 | 1.06 | 3.31 |
| Net Debt to EBITDA | -0.68 | 0.01 | 0.18 | 0.19 | 0.31 |
| Profitability Margins | |||||
| Gross Profit Margin | 73.68% | 0.00% | 54.14% | 68.18% | 100.00% |
| EBIT Margin | 1289.05% | 0.00% | -1536.29% | -2755.30% | -2709.33% |
| EBITDA Margin | 1350.27% | 0.00% | -1444.91% | -2431.61% | -2560.53% |
| Operating Profit Margin | -1536.91% | 0.00% | -1346.71% | -3600.78% | -2994.53% |
| Pretax Profit Margin | 1224.79% | 0.00% | -1548.23% | -2807.36% | -2831.20% |
| Net Profit Margin | 1223.08% | 0.00% | -1548.23% | -2807.36% | -2831.20% |
| Continuous Operations Profit Margin | 1223.08% | 0.00% | -1548.23% | -2807.36% | -2831.20% |
| Net Income Per EBT | 99.86% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | -79.69% | 99.26% | 114.96% | 77.97% | 94.55% |
| Return on Assets (ROA) | 32.42% | -58.51% | -84.67% | -61.82% | -106.72% |
| Return on Equity (ROE) | 44.71% | -144.75% | -365.49% | -148.34% | -200.47% |
| Return on Capital Employed (ROCE) | -47.08% | -69.53% | -93.19% | -90.22% | -142.68% |
| Return on Invested Capital (ROIC) | -43.98% | -64.80% | -91.39% | -87.47% | -138.68% |
| Return on Tangible Assets | 32.42% | -58.51% | -84.67% | -61.82% | -108.61% |
| Earnings Yield | 25.51% | -27.88% | -50.59% | -163.93% | -253.74% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.87 | 0.00 | 1.43 | 7.52 | 1.00 |
| Payables Turnover | 0.19 | 0.84 | 0.86 | 0.25 | 0.00 |
| Inventory Turnover | 0.28 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.42 | 0.00 | 0.44 | 0.13 | 0.14 |
| Asset Turnover | 0.03 | 0.00 | 0.05 | 0.02 | 0.04 |
| Working Capital Turnover Ratio | 0.04 | 0.00 | 0.08 | 0.03 | 0.06 |
| Cash Conversion Cycle | -149.72 | -432.05 | -167.66 | -1420.39 | 365.00 |
| Days of Sales Outstanding | 421.13 | 0.00 | 254.87 | 48.53 | 365.00 |
| Days of Inventory Outstanding | 1308.71 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1879.56 | 432.05 | 422.54 | 1468.92 | 0.00 |
| Operating Cycle | 1729.84 | 0.00 | 254.87 | 48.53 | 365.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.44 | -1.36 | -1.73 | -5.53 | -16.67 |
| Free Cash Flow Per Share | -1.59 | -1.42 | -1.75 | -5.55 | -17.73 |
| Dividend Paid and CapEx Coverage Ratio | -9.57 | -22.90 | -111.81 | -334.48 | -15.82 |
| Capital Expenditure Coverage Ratio | -9.57 | -22.90 | -111.81 | -334.48 | -15.82 |
| Operating Cash Flow Coverage Ratio | -3.06 | -2.43 | -6.85 | -5.70 | -7.00 |
| Operating Cash Flow to Sales Ratio | -13.11 | 0.00 | -10.57 | -30.75 | -21.89 |
| Free Cash Flow Yield | -30.21% | -25.57% | -34.86% | -180.11% | -208.57% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 3.93 | -3.59 | -1.98 | -0.61 | -0.39 |
| Price-to-Sales (P/S) Ratio | 47.95 | 0.00 | 30.60 | 17.13 | 11.16 |
| Price-to-Book (P/B) Ratio | 1.75 | 5.19 | 7.22 | 0.90 | 0.79 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.31 | -3.91 | -2.87 | -0.56 | -0.48 |
| Price-to-Operating Cash Flow Ratio | -3.66 | -4.08 | -2.89 | -0.56 | -0.51 |
| Price-to-Earnings Growth (PEG) Ratio | -0.02 | 0.09 | 0.04 | 0.01 | 0.07 |
| Enterprise Value Multiple | 2.87 | -4.03 | -1.94 | -0.51 | -0.13 |
| Enterprise Value | 225.59M | 228.33M | 98.04M | 17.62M | 9.91M |
| EV to EBITDA | 2.87 | -4.03 | -1.94 | -0.51 | -0.13 |
| EV to Sales | 38.76 | 0.00 | 28.01 | 12.46 | 3.30 |
| EV to Free Cash Flow | -2.68 | -3.91 | -2.63 | -0.40 | -0.14 |
| EV to Operating Cash Flow | -2.96 | -4.08 | -2.65 | -0.41 | -0.15 |
| Tangible Book Value Per Share | 3.01 | 1.07 | 0.69 | 3.40 | 10.41 |
| Shareholders’ Equity Per Share | 3.01 | 1.07 | 0.69 | 3.40 | 10.76 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.11 | 0.00 | 0.16 | 0.18 | 0.76 |
| Net Income Per Share | 1.34 | -1.55 | -2.53 | -5.05 | -21.57 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.95 | 1.07 | 1.01 | 1.02 | 1.04 |
| Research & Development to Revenue | 4.61 | 0.00 | 8.88 | 20.48 | 12.91 |
| SG&A to Revenue | 11.17 | 0.00 | 5.43 | 12.20 | 7.21 |
| Stock-Based Compensation to Revenue | 1.85 | 0.00 | 1.36 | 2.16 | 2.97 |
| Income Quality | -1.07 | 0.88 | 0.68 | 1.10 | 0.77 |
Currency in USD